HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference...
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data...
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of...
- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 --...
Celldex to Participate in the Leerink Partners Global Biopharma Conference
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
Celldex Therapeutics Announces Closing of Public Offering of Common Stock
Celldex Therapeutics to Present at TD Cowens 44th Annual Health Care Conference
Celldex Announces Pricing of Upsized $400M Public Offering of Common Stock
HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Celldex or the Company) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market...